showed in vitro synergism (CombI < 0.7) between a Bcl‐2 inhibitor and the ChT drug irinotecan and that this combination reduced tumor size in a mouse model of non‐small cell lung cancer [60]. This evidence concerns the gene BCL2 and lung cancer.